published-canonicalcomparisonmaha-epistemic/1.0

Off-target nomination versus confirmation

The cited study compares in-vitro CHANGE-seq nominations with cellular off-target activity and shows that genomic context and individual variation affect correspondence. Within this page, that proposition is limited to The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity.

Substantial reference · 9 evidence dimensions · maha-substantial-publication/1.5

Bounded definition

The cited study compares in-vitro CHANGE-seq nominations with cellular off-target activity and shows that genomic context and individual variation affect correspondence. Within this page, that proposition is limited to The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity.

Definition and evidence boundary

A distinction between assays that identify candidate sites and cellular measurements that confirm editing frequency under matched conditions. The bounded proposition retained by the canonical record is: The cited study compares in-vitro CHANGE-seq nominations with cellular off-target activity and shows that genomic context and individual variation affect correspondence.

The applicable scope is The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity. This definition must not be generalized beyond the cited source and exact record boundary.

Claims: urn:maha:claim:off-target-nomination-versus-confirmation

Mechanism and technical context

The study develops an in-vitro circularized-DNA assay for Cas9 activity and compares nominations with cellular activity and genomic context for specified targets. This is the source-bound technical context for the record; no uncited mechanism is added by the compiler.

A nominated site is not automatically edited in cells, while a non-nominated site is not proof of absolute absence below every detection limit. The mechanism or method is therefore presented as one component of a larger system, not as evidence for every downstream outcome.

Claims: urn:maha:claim:off-target-nomination-versus-confirmation

How to interpret the evidence

There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices. The evidence maturity recorded here is single study, and the claim kind is empirical claim.

This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded. In-vitro nomination is not identical to editing frequency or biological consequence in a treated cell population or organism. These qualifications travel with the claim whenever it is reused.

Claims: urn:maha:claim:off-target-nomination-versus-confirmation

What the source supports and what remains unknown

The inspected source supports exactly this: The study develops an in-vitro circularized-DNA assay for Cas9 activity and compares nominations with cellular activity and genomic context for specified targets. It was read at Abstract; Figures 1–6; Methods; datasets PRJNA625995 and GSE149295.

What remains unknown is everything outside that locator. A nominated site is not automatically edited in cells, while a non-nominated site is not proof of absolute absence below every detection limit. No quantity, comparison, or downstream outcome is established here unless a separately scoped record measures it.

Claims: urn:maha:claim:off-target-nomination-versus-confirmation

Source identity, locator, and reuse boundary

The bound source is “CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity” by Christopher R. Lazzarotto, Nhu T. Nguyen, J. A. Tangprasertchai, S. C. Malagon-Lopez, et al., published by Nature Biotechnology on 2020-06-22; its declared stable identity is doi:10.1038/s41587-020-0555-7.

The inspected-content locator is Abstract; Figures 1–6; Methods; datasets PRJNA625995 and GSE149295. Reuse is limited to citation-with-paraphrase. Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced. This metadata establishes source identity and inspection scope, not the truth of claims outside the cited locator.

Claims: urn:maha:claim:off-target-nomination-versus-confirmation

Comparison and calculation boundary

Applicability is decided explicitly, not filled with generic material.

Comparison · not-applicable

This record carries 1 source-bound proposition and therefore has no second supported side. A comparison would have to be manufactured from an adjacent title rather than from a second inspected claim, which the gate forbids.

Calculation · not-applicable

The canonical claim declares no reproducible numerical inputs, equation, units, or uncertainty propagation; recorded uncertainty kind is qualitative. Supplying sample values would invent an unsupported quantitative result.

Limitations and prohibited inference

The claim stops where its evidence stops.

  • record boundary

    A nominated site is not automatically edited in cells, while a non-nominated site is not proof of absolute absence below every detection limit.

  • record boundary

    A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record.

  • prohibited inference

    Do not treat the off-target nomination versus confirmation record as medical advice, a treatment recommendation, or evidence of general clinical readiness.

  • prohibited inference

    Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract.

  • editorial

    This compilation reorganizes an existing inspected claim and its declared source; it does not add a new experiment, measurement, or independent replication.

  • editorial

    Internal editorial inspection is not external peer review, and no result on this page has been independently reproduced.

Related records and mathematical bridges

application

CHANGE-seq off-target nomination

Declared strategic-dependency edge from this record. The edge is navigational and asserts no equivalence or causation beyond the cited source scope.

Selection: bridge edge

application

GUIDE-seq off-target detection

Declared strategic-dependency edge from this record. The edge is navigational and asserts no equivalence or causation beyond the cited source scope.

Selection: bridge edge

When no declared bridge edge is present, related records are linked by shared evidence or canonical domain adjacency. Those links are navigational and do not claim mathematical or physical equivalence.

Connected domain graph

Typed dependencies preserve publication state.

Only independently canonical records receive public links and relation statements. Draft graph topology remains private.

mechanistic dependencycanonical

GUIDE-seq off-target detection

inbound connection · method

GUIDE-seq produces a nomination set that requires orthogonal confirmation and frequency measurement.

mechanistic dependencycanonical

CHANGE-seq off-target nomination

inbound connection · method

CHANGE-seq nominations require cellular confirmation under matched editor and delivery conditions.

Claim ledger

Every proposition keeps its own evidence state.

empirical-claimsingle-study

The cited study compares in-vitro CHANGE-seq nominations with cellular off-target activity and shows that genomic context and individual variation affect correspondence.

Scope
The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity.
Boundary
A nominated site is not automatically edited in cells, while a non-nominated site is not proof of absolute absence below every detection limit.
Uncertainty
There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices.
Replication
This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.

Primary sources

Citation, locator, rights, and boundary travel together.

  1. Source 1 · Nature Biotechnology

    CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity

    Christopher R. Lazzarotto, Nhu T. Nguyen, J. A. Tangprasertchai, S. C. Malagon-Lopez, et al.

    Exact locator
    Abstract; Figures 1–6; Methods; datasets PRJNA625995 and GSE149295.
    Establishes
    The study develops an in-vitro circularized-DNA assay for Cas9 activity and compares nominations with cellular activity and genomic context for specified targets.
    Boundary
    In-vitro nomination is not identical to editing frequency or biological consequence in a treated cell population or organism.
    Rights basis
    citation with paraphrase · Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.
    Declared interests
    The article declares patent and company relationships involving genome-editing assays and therapeutics.